Previous 10 | Next 10 |
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA PR Newswire BEIJING , Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and p...
2023-08-11 07:45:03 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q2 GAAP EPS of -$0.77. Revenue of $9.82M (+14.6% Y/Y). As of June 30, 2023, CASI had cash, cash equivalents and short-term investments of $36.8 million. For further details see: CASI ...
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES PR Newswire BEIJING , Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative thera...
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals PR Newswire BEIJING , Aug. 1, 2023 /PRNewswire/ -- CASI Ph...
2023-07-23 05:45:00 ET Summary Novartis has signed a $1 billion deal to acquire DTx Pharma - DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. Sichuan Kelun-Biotech completed a $174 million IPO on the Hong Kong Exchange, valuing the co...
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 PR Newswire BEIJING , July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing an...
2023-05-17 08:06:14 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q1 GAAP EPS of -$0.45. Revenue of $8.35M (-7.8% Y/Y). For further details see: CASI Pharmaceuticals GAAP EPS of -$0.45, revenue of $8.35M
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire BEIJING , May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...
2023-04-26 13:30:58 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q4 GAAP EPS of -$3.01 misses by $2.64 . Revenue of $43.12M beats by $32.31M . For further details see: CASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M ...
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 PR Newswire BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commerc...
News, Short Squeeze, Breakout and More Instantly...
CASI Pharmaceuticals Inc. Company Name:
CASI Stock Symbol:
NASDAQ Market:
CASI Pharmaceuticals Inc. Website:
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR Newswire BEIJING , April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercia...
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR Newswire BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing a...